Molecular Aspects of Co-morbidities in COVID-19 Infection

Document Type : CURRENT CONCEPTS REVIEW

Authors

1 1 Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran 2 Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

3 1 Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran 2 Department of Medical Genetics, Faculty of Medicine

Abstract

Coronaviruses are a group of enveloped viruses with single-stranded non-segmented positive-sense RNA genomes. In
December 2019, SARS-CoV-2 appeared in China for the first time and quickly spread throughout the world. Although
certain medications suggested for other afflictions tend to be potentially effective for curing the infection, there is no
approved vaccination or drug available for this virus yet. Comprehension of the disease molecular pathogenesis could
provide useful tools for COVID-19 patients in surveillance, prognosis, treatment, vaccine development and therapeutic
targeting. The present research aims to summarize the association in COVID-19 patients between molecular dimensions
of comorbidities with clinical and preclinical information.
Developing an ACE2 inhibitor could be a possible therapeutic target. Plasmin is another possible candidate both in
diagnosis and treatment areas. All predicted biomarkers must be validated either through randomized clinical trials or
experimental assays before clinical application in patients.
Level of evidence: V

Keywords

The Archives of Bone and Joint Surgery

Volume 8, Supplement 1
April 2020
Pages 226-230

Files

History

  • Receive Date: 13 April 2020
  • Accept Date: 15 April 2020

Share

How to cite

Statistics